CRDF Valuation

Cardiff Oncology Inc

Add to Watchlist

Advanced Chart

2.470

+0.090(+3.780%)

Overview
Forecast
Valuation

CRDF Relative Valuation

CRDF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRDF is overvalued; if below, it's undervalued.

Historical Valuation

Cardiff Oncology Inc (CRDF) is now in the Fair zone, suggesting that its current forward PS ratio of 554.16 is considered Fairly compared with the five-year average of 789.89. The fair price of Cardiff Oncology Inc (CRDF) is between 0.32 to 5.69 according to relative valuation methord.

Relative Value

Fair Zone

0.32-5.69

Current Price：2.47

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.98

P/B

Median3y

1.51

Median5y

2.60

-23.86

FCF Yield

Median3y

-36.99

Median5y

-28.38

Competitors Valuation Multiple

The average P/S ratio for CRDF's competitors is 185.02, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF) exhibits a P/S ratio of 554.16, which is 199.52% above the industry average. Given its robust revenue growth of -3.21%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap